Sadykov Nariman, Soyama Akihiko, Hidaka Masaaki, Kinoshita Ayaka, Takatsuki Mitsuhisa, Adachi Tomohiko, Kitasato Amane, Fujita Fumihiko, Kuroki Tamotsu, Eguchi Susumu
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan ; Department of HPB Surgery, Syzganov's National Scientific Center of Surgery, Almaty, Kazakhstan.
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Case Rep Gastroenterol. 2015 Jan 24;9(1):29-35. doi: 10.1159/000375117. eCollection 2015 Jan-Apr.
It is well known that the presence of end-stage liver disease increases the risk of developing hepatocellular carcinoma (HCC). Liver transplantation (LT) for patients within the Milan criteria has become a standard treatment for HCC in most developed centers worldwide. However, a major cause of death in cirrhotic patients with HCC after transplantation is tumor recurrence, including peritoneal recurrences, which develops rarely but presents a significant problem with regard to their management. Our experience includes two cases with HCC within the Milan criteria of peritoneal recurrences after living donor LT. Both patients had interventions for HCC in their medical history before LT, and we propose that these might have been a possible cause of the HCC peritoneal recurrence.
众所周知，终末期肝病的存在会增加肝细胞癌（HCC）的发生风险。对于符合米兰标准的患者，肝移植（LT）已成为全球大多数发达中心治疗HCC的标准方法。然而，肝硬化合并HCC患者移植后死亡的主要原因是肿瘤复发，包括腹膜复发，腹膜复发很少发生，但在其管理方面是一个重大问题。我们的经验包括两例符合米兰标准的HCC患者在活体供肝LT后发生腹膜复发。两名患者在LT前的病史中均有过针对HCC的干预治疗，我们认为这些可能是HCC腹膜复发的一个潜在原因。
